Plain-English translation of NCT06311214 on ClinicalTrials.gov ↗ ·
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether personalized cancer treatment works better when doctors match patients to specific antibody-drug conjugate medications based on genetic and protein tests of their tumor. The study will enroll about 500 patients with advanced solid cancers that have spread or cannot be cured with standard therapy. Researchers want to see if this personalized approach—tailoring the medication to match what's unique about each person's tumor—helps more patients respond to treatment.
Many cancer patients run out of treatment options after standard therapies stop working. This trial exists to find out whether testing tumors for specific genetic markers can help doctors choose the right advanced medication for each patient, potentially improving survival and quality of life for people with advanced cancers.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will first have genetic and protein testing of your tumor to see if it matches one of the study medications. If it does, you'll be assigned to receive one of two antibody-drug conjugate medications as an intravenous infusion (into your vein) every 2–4 weeks, depending on which medication you receive. Throughout the trial, you'll have regular imaging scans, blood draws, and biopsies to monitor how your cancer responds and to help researchers understand how the medication is working in your body.
AI-generated summary from trial data · Sep 18, 2026 · Not medical advice
United States